Education
About Us
Working with TipRanks
Follow Us
CollPlant Biotechnologies Ltd. (CLGN)
:CLGN
CLGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.31 - $5.45
Previous CloseN/A
Volume800.00
Average Volume (3M)56.96K
Market Cap
$40.05M
Enterprise Value$21.42M
Total Cash (Recent Filing)$11.91M
Total Debt (Recent Filing)$3.08M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 20, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding12,716,014
10 Day Avg. Volume41,540
30 Day Avg. Volume56,960
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue41.58
Enterprise Value/Gross Profit-15.41
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$2.50Price Target Upside-20.63% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
PartnershipsCollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.
Product DevelopmentEncouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.
Bears Say
Financial PerformanceThe company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.
Collplant Holdings News
CLGN FAQ
What was CollPlant Biotechnologies Ltd.’s price range in the past 12 months?
CollPlant Biotechnologies Ltd. lowest stock price was $1.31 and its highest was $5.45 in the past 12 months.
What is CollPlant Biotechnologies Ltd.’s market cap?
CollPlant Biotechnologies Ltd.’s market cap is $40.05M.
When is CollPlant Biotechnologies Ltd.’s upcoming earnings report date?
CollPlant Biotechnologies Ltd.’s upcoming earnings report date is Aug 20, 2025 which is in 6 days.
How were CollPlant Biotechnologies Ltd.’s earnings last quarter?
CollPlant Biotechnologies Ltd. released its earnings results on May 28, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.17.
Is CollPlant Biotechnologies Ltd. overvalued?
According to Wall Street analysts CollPlant Biotechnologies Ltd.’s price is currently Overvalued.
Does CollPlant Biotechnologies Ltd. pay dividends?
CollPlant Biotechnologies Ltd. does not currently pay dividends.
What is CollPlant Biotechnologies Ltd.’s EPS estimate?
CollPlant Biotechnologies Ltd.’s EPS estimate is -0.1.
How many shares outstanding does CollPlant Biotechnologies Ltd. have?
CollPlant Biotechnologies Ltd. has 12,716,014 shares outstanding.
What happened to CollPlant Biotechnologies Ltd.’s price movement after its last earnings report?
CollPlant Biotechnologies Ltd. reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 76.166%.
Which hedge fund is a major shareholder of CollPlant Biotechnologies Ltd.?
Currently, no hedge funds are holding shares in CLGN
Collplant Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.50 (-20.63% Downside)
$2.50 (-20.63% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.23%
12-Months-Change
Fundamentals
Return on Equity
-75.27%
Trailing 12-Months
Asset Growth
-43.19%
Trailing 12-Months
Company Description
CollPlant Biotechnologies Ltd.
Collplant Holdings (CLGN) is a biotechnology company specializing in regenerative medicine and tissue repair. The company focuses on developing innovative solutions based on its proprietary collagen technology, which is derived from genetically modified tobacco plants. Collplant's core products include a range of collagen-based therapies and medical devices aimed at enhancing wound healing, tissue regeneration, and reconstructive surgery. The company operates primarily in the healthcare sector, targeting applications in orthopedics, aesthetic medicine, and other areas requiring tissue reconstruction and repair.
CLGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.View all CLGN earnings summariesCLGN Stock 12 Month Forecast
Average Price Target
$2.50
▼(-20.63% Downside)
Technical Analysis
PolyPid
―
ALX Oncology Holdings
―
Spruce Biosciences
―
Aligos Therapeutics
―
Sensei Biotherapeutics
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
11.10% Other Institutional Investors
88.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---